NTP panel peer reviews substances for potential listing as carcinogens
By Ernie Hood
A panel of experts peer-reviewed the two most recent NTP draft Report on Carcinogens (RoC) documents, known as monographs, at a public meeting Dec. 12-13 at NIEHS.
The panel was charged with reviewing the draft monographs for ortho-Toluidine (http://ntp.niehs.nih.gov/NTP/About_NTP/MonoPeerRvw/2013/October/oTol_PeerRevDraft_508BE.pdf) and pentachlorophenol and by-products of its synthesis (http://ntp.niehs.nih.gov/NTP/About_NTP/MonoPeerRvw/2013/October/PCPPeerRevDraft_508BE.pdf) The monographs contain the rationale and background information to support NTP listing recommendations for inclusion in the RoC. The panel voted on whether the scientific evidence supports the listing recommendations, which can characterize a substance as either “known to be human carcinogens” or as “reasonably anticipated to be human carcinogens.”
After thoughtful discussions, the panel (http://ntp.niehs.nih.gov/NTP/About_NTP/MonoPeerRvw/2013/December/Roster20131212_508.pdf) chaired by Kenneth McMartin, Ph.D., a professor in the Department of Pharmacology, Toxicology, and Neuroscience at Louisiana State University Health Sciences Center, recommended listing ortho-Toluidine as a known human carcinogen and pentachlorophenol and by-products of its synthesis as reasonably anticipated to be a human carcinogen.
Monograph on ortho-Toluidine
The substance ortho-Toluidine is used to make dyes, rubber chemicals, herbicides, and the local anesthetic prilocaine. It has been listed in the RoC since 1983 as reasonably anticipated to be a human carcinogen. Since then, several cancer studies have been published in peer-reviewed literature, and the International Agency for Research on Cancer (http://www.iarc.fr/) (IARC) has concluded that the compound is carcinogenic to humans. For these reasons, it was selected for a reevaluation and a possible change in RoC listing status.
NTP staff highlighted studies, presented in the draft monograph, showing credible evidence of an association between urinary-bladder cancer and exposure to ortho-Toluidine, based on consistent findings across human studies. Evidence from studies in experimental animals and on mechanisms of carcinogenicity also supports that finding. The peer-review panel unanimously concurred with the NTP’s preliminary listing recommendation that ortho-Toluidine is known to be a human carcinogen.
Monograph on pentachlorophenol and by-products of its synthesis
Studies evaluating the carcinogenicity of pentachlorophenol and by-products of its synthesis were discussed in great length and detail among the peer-review panel and RoC staff, to determine if there was sufficient evidence to support NTP’s preliminary listing recommendation of known to be a human carcinogen, with non-Hodgkin's lymphoma as the primary cancer endpoint of concern in these studies.
Pentachlorophenol is a chlorinated aromatic compound that was used in the U.S. as a commercial and residential wood preservative and multipurpose biocide, until its was restricted in the mid-1980s to non-residential use. Today, it is limited to commercial wood preservation in items such as utility poles, fence posts, and railroad ties.
The panel members stated that overall the evidence of carcinogenicity from the studies in human cancer was limited. They agreed that there was one very good study that found an association between exposure to pentachlorophenol and by-products of its synthesis, but thought the evidence from the other studies was much more limited, due to their small size and potential for confounding factors.
The panel also struggled over whether the candidate substance should be pentachlorophenol itself or pentachlorophenol and the byproducts of its synthesis. Technical-grade pentachlorophenol is a mixture, with up to 10 percent of the substance being by-products of its synthesis, many of which are dioxin-like compounds that may contribute to its carcinogenicity.
At the end of the day, the panel voted to recommend changing the NTP preliminary listing decision of known to be human carcinogen, to reasonably anticipated to be a human carcinogen, based on limited evidence from studies in humans. The listing recommendation also took into consideration the sufficient evidence of carcinogenicity of pentachlorophenol, and pentachlorophenol and by-products of its synthesis, from studies in experimental animals and supporting mechanistic evidence.
The NTP will consider the panel’s comments and public comments, as it makes revisions to the draft monographs. The updated monographs will be presented to the NTP Board of Scientific Counselors at the next meeting in April 2014.
(Ernie Hood is a contract writer with the NIEHS Office of Communications and Public Liaison.)